Gates MRI- COD-01-T01-01 Amendment 1

Targeted Disease(s):
COVID-19

Purpose of Study:

A randomized, controlled, Phase 2b study to evaluate safety and efficacy of rivaroxaban(Xarelto®) for high risk people with mild COVID-19.

Study Dates:
September 1, 2020 - Ongoing

Type of Study:
Pre-Market

Study Design:
Controlled Design

Study Location:
Nationwide

Lead Institution:
Allergy & Asthma Medical Group and Research Center A P.C

Funding Source:
Bill & Melinda Gates Medical Research Institute

ClinicalTrails.gov Identifier:
NCT04504032

Register for Trial
Freedom From Smoking Clinic
, | Sep 29, 2021
Community Connections: The Path To Clean Air
, | Oct 06, 2021